{
  "company": "Qiagen N.V.",
  "ticker": "QGEN",
  "period": {
    "from": "2026-03-16",
    "to": "2026-04-15",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 16,
    "negative": 10,
    "neutral": 32
  },
  "synthesis": {
    "executive_summary": "Sentiment analysis for Qiagen N.V. (QGEN) from 2026-03-16 to 2026-04-15. Analyzed 58 items across FDA and news sources.",
    "key_findings": [],
    "overall_sentiment": "neutral"
  },
  "top_positive": [
    {
      "title": "Molecular Tumor Board Solutions Market Outlook 2026-2030 & 2035 with Competitor Market Share Data",
      "date": "2026-04-07",
      "source": "news",
      "score": 0.832
    },
    {
      "title": "Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities",
      "date": "2026-03-27",
      "source": "alpha_vantage",
      "score": 0.637
    },
    {
      "title": "Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities",
      "date": "2026-03-27",
      "source": "alpha_vantage",
      "score": 0.637
    },
    {
      "title": "Qiagen N.V. stock (NL0012169213): Is sample-to-insight leadership strong enough to unlock new upside",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": 0.511
    },
    {
      "title": "Qiagen N.V. Stock: Oversold Opportunity in Molecular Diagnostics Leader for North American Investors",
      "date": "2026-04-01",
      "source": "alpha_vantage",
      "score": 0.421
    },
    {
      "title": "Qiagen N.V. Stock: Oversold Opportunity in Sample-to-Insight Leader Amid Biotech Sector Shifts",
      "date": "2026-04-01",
      "source": "alpha_vantage",
      "score": 0.421
    },
    {
      "title": "Qiagen N.V. stock rises on strong Q4 earnings and genomics demand surge amid AI biotech push",
      "date": "2026-03-20",
      "source": "alpha_vantage",
      "score": 0.421
    },
    {
      "title": "Qiagen N.V. Stock: Leader in Molecular Diagnostics Faces CEO Transition Amid Steady Growth Outlook",
      "date": "2026-04-01",
      "source": "alpha_vantage",
      "score": 0.382
    },
    {
      "title": "PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act]",
      "date": "2026-03-20",
      "source": "alpha_vantage",
      "score": 0.296
    },
    {
      "title": "Human Identification Market worth $1.69 billion by 2031 | MarketsandMarkets™",
      "date": "2026-03-27",
      "source": "news",
      "score": 0.226
    }
  ],
  "top_negative": [
    {
      "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider",
      "date": "2026-04-13",
      "source": "news",
      "score": -0.869
    },
    {
      "title": "Predictive Biomarkers Market to Reach USD 156.85 Billion by 2035; Rising Adoption of Precision Medicine and Targeted Therapies Driving Market Growth – SNS Insider",
      "date": "2026-03-17",
      "source": "news",
      "score": -0.477
    },
    {
      "title": "QIAGEN NV Hits New 52-Week Low at USD 39.26 Amid Ongoing Decline",
      "date": "2026-03-26",
      "source": "alpha_vantage",
      "score": -0.473
    },
    {
      "title": "Qiagen N.V. stock faces pressure amid biotech sector volatility and recent market caution",
      "date": "2026-03-26",
      "source": "alpha_vantage",
      "score": -0.296
    },
    {
      "title": "Qiagen N.V. stock faces pressure amid biotech sector volatility and recent price dip on Frankfurt exchange",
      "date": "2026-03-25",
      "source": "alpha_vantage",
      "score": -0.296
    },
    {
      "title": "Qiagen N.V. stock faces pressure amid genomics slowdown as DACH investors eye biotech resilience",
      "date": "2026-03-22",
      "source": "alpha_vantage",
      "score": -0.296
    },
    {
      "title": "Precision Trading with Qiagen N.v. (QGEN) Risk Zones",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": -0.273
    },
    {
      "title": "QIAGEN NV Hits New 52-Week Low at USD 38.80 Amid Declining Performance",
      "date": "2026-03-30",
      "source": "alpha_vantage",
      "score": -0.273
    },
    {
      "title": "Qiagen (NYSE:QGEN) Sets New 52-Week Low - Time to Sell?",
      "date": "2026-03-27",
      "source": "alpha_vantage",
      "score": -0.273
    },
    {
      "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider",
      "date": "2026-04-03",
      "source": "news",
      "score": -0.226
    }
  ],
  "raw_data": {
    "total_items": 58,
    "items": [
      {
        "source": "alpha_vantage",
        "title": "Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel",
        "url": "https://www.biospectrumasia.com/news/107/27504/qiagen-expands-into-bloodstream-infection-syndromic-testing-with-new-rapid-qiastat-dx-panel.html",
        "date": "2026-04-15",
        "summary": "Qiagen has launched its CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel, marking its expansion into syndromic testing for bloodstream infections. This new rapid panel can identify 20 gram-positive bacterial and fungal pathogens and 10 antimicrobial resistance markers from blood cultures, delivering results in about one hour. The QIAstat-Dx BCID GPF Plus AMR Panel aims to provide critical information for patient management, antimicrobial stewardship, and infection control.",
        "sentiment_score": 0.513477,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.103,
          "confidence": 0.1
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Why does its sample-to-insight business model matter more for U.S.",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-why-does-its-sample-to-insight-business/69154718",
        "date": "2026-04-15",
        "summary": "Qiagen N.V.'s \"sample-to-insight\" business model is increasingly relevant for US investors due to its focus on automated solutions for molecular diagnostics and research, directly supporting precision medicine. This model provides exposure to stable demand from labs and pharma, emphasizing scalable automation and recurring revenue from consumables. Analysts view this approach favorably for its resilience, competitive moat, and alignment with high-growth areas like genomics and infectious disease",
        "sentiment_score": 0.806494,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen launches bloodstream infection testing panel By Investing.com",
        "url": "https://ca.investing.com/news/company-news/qiagen-launches-bloodstream-infection-testing-panel-93CH-4564707",
        "date": "2026-04-14",
        "summary": "QIAGEN N.V. announced the launch of its QIAstat-Dx BCID GPF Plus AMR Panel, entering the syndromic testing market for bloodstream infections. This CE-IVDR-certified panel quickly identifies 20 gram-positive bacterial and fungal pathogens and 10 antimicrobial resistance markers within about an hour. The company is poised to present this new panel at the ESCMID Global 2026 Congress while also contemplating strategic options, including a potential sale, amidst recent analyst upgrades and leadership",
        "sentiment_score": 0.314565,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN launches bloodstream infection testing panel",
        "url": "https://www.streetinsider.com/Corporate+News/QIAGEN+launches+bloodstream+infection+testing+panel/26311984.html",
        "date": "2026-04-14",
        "summary": "QIAGEN N.V. (NYSE: QGEN) has launched its QIAstat-Dx BCID GPF Plus AMR Panel for bloodstream infection testing, a CE-IVDR-certified panel that identifies 20 gram-positive bacterial and fungal pathogens and 10 antimicrobial resistance markers. This expansion moves QIAGEN's QIAstat-Dx portfolio into bloodstream infection applications, building on its existing respiratory, gastrointestinal, and meningitis testing. The company announced the product launch at the ESCMID Global 2026 Congress and plans",
        "sentiment_score": 0.423667,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel",
        "url": "https://www.businesswire.com/news/home/20260414262531/en/QIAGEN-Expands-Into-Bloodstream-Infection-Syndromic-Testing-With-New-Rapid-QIAstat-Dx-Panel",
        "date": "2026-04-14",
        "summary": "QIAGEN has launched the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel, expanding its syndromic testing portfolio into bloodstream infections. This new panel rapidly identifies 20 gram-positive bacterial and fungal pathogens and 10 antimicrobial resistance markers from positive blood cultures, providing results in about an hour. The expansion aims to facilitate faster clinical decision-making, antimicrobial stewardship, and infection control for bloodstream infections.",
        "sentiment_score": 0.405854,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.103,
          "confidence": 0.1
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Precision Trading with Qiagen N.v. (QGEN) Risk Zones",
        "url": "https://news.stocktradersdaily.com/news_release/134/Precision_Trading_with_Qiagen_N.v._QGEN_Risk_Zones_041426091002_1776172202.html",
        "date": "2026-04-14",
        "summary": "This article by Stock Traders Daily provides a detailed analysis of Qiagen N.v. (QGEN), highlighting a near-term strong sentiment with a neutral mid and long-term outlook. It outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry/target/stop loss zones, generated by AI models for different risk profiles. The analysis also includes multi-timeframe signal data for support and resistance levels.",
        "sentiment_score": 0.321485,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Is sample-to-insight leadership strong enough to unlock new upside",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-is-sample-to-insight-leadership-strong/69144198",
        "date": "2026-04-14",
        "summary": "This report analyzes Qiagen N.V.'s business model, its relevance in the U.S. and English-speaking markets, and the risks involved for investors. Qiagen focuses on sample-to-insight solutions in molecular diagnostics and life sciences, generating recurring revenue from high-margin consumables like reagents and kits. The company's growth is fueled by global demand for molecular diagnostics, advancements in gene and cell therapy, and its strong competitive position in sample prep technologies, thou",
        "sentiment_score": 0.475085,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Why does its molecular diagnostics edge matter more now for U.S. investors?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-why-does-its-molecular-diagnostics-edge/69143141",
        "date": "2026-04-14",
        "summary": "The article discusses why Qiagen N.V.'s molecular diagnostics capabilities are increasingly relevant for U.S. investors, highlighting the company's \"sample-to-insight\" business model and its comprehensive portfolio of tools. It covers key products, industry drivers, competitive strengths, and analyst views, while also addressing potential risks such as supply chain vulnerabilities and regulatory hurdles. Qiagen's focus on precise genomic testing and personalized medicine positions it as a key pl",
        "sentiment_score": 0.531381,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock (NL0012169213): Does its genomics leadership deliver the biotech stability U.S. investors seek?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-does-its-genomics-leadership-deliver-the/69132422",
        "date": "2026-04-12",
        "summary": "Qiagen N.V., a leader in molecular diagnostics and life sciences tools, offers U.S. investors exposure to the growing genomics market through its Nasdaq listing. The company's business model relies on recurring revenue from consumables for sample preparation and analysis, providing stability in the biotech sector. With strong positions in key markets like North America and a focus on precision medicine, Qiagen is considered a steady compounder by analysts despite potential risks like reimburseme",
        "sentiment_score": 0.49718,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Massachusetts Financial Services Co. MA Increases Stock Position in Qiagen N.V. $QGEN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-massachusetts-financial-services-co-ma-increases-stock-position-in-qiagen-nv-qgen-2026-04-11/",
        "date": "2026-04-11",
        "summary": "Massachusetts Financial Services Co. MA recently increased its stock holdings in Qiagen N.V. by 1.1% during the fourth quarter, bringing its total to over 24 million shares valued at approximately $1.09 billion. This comes as Qiagen reported better-than-expected Q4 earnings and revenue, while setting optimistic guidance for FY2026. Despite a \"Hold\" consensus rating and a $55.20 price target, the stock shows mixed momentum near $40.90, with high institutional ownership.",
        "sentiment_score": 0.262603,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "How Investors May Respond To Qiagen (QGEN) Upgrade After Reaffirmed 5% Outlook And New Product Plans",
        "url": "https://www.sahmcapital.com/news/content/how-investors-may-respond-to-qiagen-qgen-upgrade-after-reaffirmed-5-outlook-and-new-product-plans-2026-04-07",
        "date": "2026-04-09",
        "summary": "Deutsche Bank upgraded Qiagen (QGEN) after the company reaffirmed its 5% growth target and highlighted new sample-preparation product launches expected in the second half of 2026. This comes as Qiagen navigates a CEO transition, discontinues some platforms, and focuses on next-generation diagnostics tools. The article suggests that while the upgrade and growth outlook instill confidence, the key for investors remains the successful execution of new product launches and management of increasing c",
        "sentiment_score": 0.422295,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QGEN PE Ratio & Valuation, Is QGEN Overvalued",
        "url": "https://intellectia.ai/en/stock/QGEN/valuation",
        "date": "2026-04-09",
        "summary": "Qiagen NV (QGEN) is currently considered undervalued, with its forward PE ratio of 12.82 significantly lower than its five-year average of 21.34. The fair price for QGEN is estimated to be between $62.67 and $75.77, compared to its current price of $41.01, indicating it is undervalued by 34.56%. While its P/S ratio is above the industry average, its strong revenue growth might not sustain this premium.",
        "sentiment_score": 0.319935,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "BlackRock Discloses Double-Digit Stake in Qiagen",
        "url": "https://www.tipranks.com/news/company-announcements/blackrock-discloses-double-digit-stake-in-qiagen",
        "date": "2026-04-08",
        "summary": "BlackRock, Inc. has reported a significant stake in Qiagen (QGEN), holding a combined capital interest of 10.67% and voting rights of 11.81% through various affiliated entities. This disclosure, made via the Dutch financial regulator AFM, highlights substantial institutional confidence in the life sciences company. Qiagen, a Netherlands-based firm specializing in molecular diagnostics, has a current average analyst rating of \"Hold\" with a $45.00 price target.",
        "sentiment_score": 0.422008,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "BlackRock Raises Substantial Stake in Qiagen to Over 10%",
        "url": "https://www.tipranks.com/news/company-announcements/blackrock-raises-substantial-stake-in-qiagen-to-over-10",
        "date": "2026-04-08",
        "summary": "Asset manager BlackRock has significantly increased its stake in Qiagen, now holding 10.66% of its share capital and 11.83% of voting rights. This enlarged, mostly indirect stake positions BlackRock as a major institutional investor, potentially influencing Qiagen's governance and market perception. Qiagen is a Netherlands-based life sciences company specializing in molecular diagnostics and listed on multiple exchanges including the NYSE.",
        "sentiment_score": 0.193714,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-04-08:newsml_PexXzGyka:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-04-08",
        "summary": "QIAGEN N.V. has released a voting rights announcement received from the AFM (Netherlands Authority For the Financial Markets) on April 8, 2026. The notification details a transaction on April 2, 2026, where BlackRock, Inc. was obliged to notify changes in its holdings in QIAGEN N.V., covering both ordinary shares and contracts for difference, held through various BlackRock entities. The announcement includes a detailed breakdown of shares and voting rights, both real and potential, highlighting ",
        "sentiment_score": 0.004057,
        "sentiment_label": "Neutral",
        "relevance_score": 0.324362,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. (NYSE:QGEN) Given Average Rating of \"Hold\" by Brokerages",
        "url": "https://www.marketbeat.com/instant-alerts/qiagen-nv-nyseqgen-given-average-rating-of-hold-by-brokerages-2026-04-04/",
        "date": "2026-04-04",
        "summary": "Twelve brokerages have given Qiagen N.V. (NYSE:QGEN) an average \"Hold\" rating, with a mean 12-month price target of $55.20. The company recently beat earnings and revenue estimates for its last quarter, posting $0.62 EPS on $540.4 million in revenue, and has provided positive guidance for fiscal year 2026. Institutional investors hold approximately 70% of the stock.",
        "sentiment_score": 0.219334,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.963745,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen (QGEN) upgraded to buy by Deutsche Bank after 30% decline",
        "url": "https://www.msn.com/en-us/money/savingandinvesting/qiagen-qgen-upgraded-to-buy-by-deutsche-bank-after-30-decline/ar-AA201X7G",
        "date": "2026-04-03",
        "summary": "Deutsche Bank has upgraded Qiagen (QGEN) stock from hold to buy following a significant 30% decline in its share price. The upgrade reflects an improved risk/reward profile for the diagnostic test maker. Analyst Mark Massaro noted that while growth concerns persist, the valuation has become more attractive.",
        "sentiment_score": 0.530882,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-04-02:newsml_PexMgJMna:0-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-04-03",
        "summary": "QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, as informed by the AFM on April 2, 2026. The notification details transactions and holdings by Bank of America Corporation, showing a total capital interest and voting rights of 3.01% in QIAGEN N.V. The reported transactions occurred on March 30, 2026, and include direct and indirect holdings through various entities.",
        "sentiment_score": 0.014634,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Bank of America Discloses 3.01% Voting Stake in Qiagen",
        "url": "https://www.tipranks.com/news/company-announcements/bank-of-america-discloses-3-01-voting-stake-in-qiagen",
        "date": "2026-04-02",
        "summary": "Bank of America Corporation and its affiliates have disclosed a 3.01% capital and voting interest in Qiagen, a Netherlands-based life sciences company. This stake comprises both actual shares and derivatives like swaps and call options, highlighting Bank of America's position as a significant institutional shareholder. The disclosure provides increased transparency regarding Qiagen's ownership structure and potential influences on its shareholder dynamics.",
        "sentiment_score": 0.33672,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QGEN Technical Analysis & Stock Price Forecast",
        "url": "https://intellectia.ai/en/stock/QGEN/technical",
        "date": "2026-04-02",
        "summary": "The article provides a technical analysis and stock price forecast for Qiagen NV (QGEN), indicating a \"Sell\" consensus based on various technical indicators as of April 6, 2026. Key metrics like MACD and moving averages suggest a bearish trend, with the stock trading below its 60-day and 200-day moving averages. Despite some neutral signals from RSI and Stochastic Oscillator, the overall recommendation points towards a sell.",
        "sentiment_score": -0.411203,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline",
        "url": "https://www.insidermonkey.com/blog/qiagen-qgen-upgraded-to-buy-by-deutsche-bank-after-30-decline-1730551/?amp=1",
        "date": "2026-04-02",
        "summary": "Deutsche Bank upgraded Qiagen N.V. (NYSE: QGEN) to Buy from Hold, maintaining a $54 price target, after the stock declined over 30% since late January. The firm notes that Qiagen’s 2026 outlook is back-end heavy, common for Diagnostics and Life Sciences companies, and is reasonably reflected in current consensus estimates. Despite macroeconomic challenges, Qiagen reiterated its 5% full-year growth estimate, anticipating improved growth in the second half due to new sample-preparation product int",
        "sentiment_score": 0.305824,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline",
        "url": "https://finance.yahoo.com/sectors/healthcare/articles/qiagen-qgen-upgraded-buy-deutsche-183727878.html",
        "date": "2026-04-02",
        "summary": "Deutsche Bank has upgraded Qiagen (QGEN) to Buy from Hold, maintaining a $54 price target, after the stock declined over 30% since late January. The firm believes the decline has priced out any buyout premium and noted that Qiagen's 2026 outlook, like many in its sector, is back-end heavy. Qiagen reiterated its 5% full-year growth estimate, anticipating improved growth in the second half due to new product introductions.",
        "sentiment_score": 0.405212,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: Oversold Opportunity in Molecular Diagnostics Leader for North American Investors",
        "url": "https://www.ad-hoc-news.de/news/ueberblick/qiagen-n-v-stock-oversold-opportunity-in-molecular-diagnostics-leader/69045464",
        "date": "2026-04-01",
        "summary": "Qiagen N.V. (NASDAQ:QGEN) shares are trading near 52-week lows, presenting a potential oversold opportunity for North American investors. Institutional investors like Allspring Global Investments have increased their stakes, and Deutsche Bank upgraded the stock to Buy, reflecting confidence in its molecular diagnostics leadership. The company's solid financial health, recurring revenue model, and strategic focus on genomics innovation position it for recovery and growth into 2026, despite broade",
        "sentiment_score": 0.484087,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: Leader in Molecular Diagnostics Faces CEO Transition Amid Steady Growth Outlook",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-leader-in-molecular-diagnostics-faces-ceo-transition/69047905",
        "date": "2026-04-01",
        "summary": "Qiagen N.V. (ISIN: NL0012169213), a prominent molecular diagnostics leader, is undergoing a CEO transition while maintaining its 5% growth target for the year. North American investors are advised to monitor leadership changes, new product launches, and the company's strategic focus on innovation and sustainability. The company's resilience, diversified portfolio, and strong position in genomics tools make it an appealing option despite sector headwinds.",
        "sentiment_score": 0.281168,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Bruker appoints QIAGEN CEO Thierry Bernard to board of directors",
        "url": "https://www.investing.com/news/company-news/bruker-appoints-qiagen-ceo-thierry-bernard-to-board-of-directors-93CH-4592749",
        "date": "2026-04-01",
        "summary": "Bruker Corporation has appointed Thierry Bernard, the current CEO of QIAGEN N.V., to its board of directors, effective immediately. Bernard, who will step down from QIAGEN upon the appointment of his successor, brings extensive experience from his leadership roles at QIAGEN and bioMérieux SA. Frank Laukien, Bruker's CEO, stated that Bernard's expertise will aid the company's growth in life-science research, biopharma, and diagnostic solutions.",
        "sentiment_score": 0.012765,
        "sentiment_label": "Neutral",
        "relevance_score": 0.332902,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: Oversold Opportunity in Sample-to-Insight Leader Amid Biotech Sector Shifts",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-oversold-opportunity-in-sample-to-insight-leader-amid/69042402",
        "date": "2026-04-01",
        "summary": "Qiagen N.V. shares are trading near 52-week lows, presenting a potentially oversold opportunity for North American investors interested in the molecular diagnostics and life sciences sector. The company, a leader in Sample-to-Insight solutions, has received analyst upgrades and seen increased institutional interest despite recent market pressure. Its strategic focus on high-growth areas like next-generation sequencing and precision medicine, coupled with its strong balance sheet, positions it fo",
        "sentiment_score": 0.318589,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "alpha_vantage",
        "title": "The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus Evidence - Learn Why",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-qgen/qiagen/news/the-bull-case-for-qiagen-qgen-could-change-following-new-qua",
        "date": "2026-03-30",
        "summary": "Qiagen (QGEN) recently released new clinical and health economic data for its QuantiFERON-TB Gold Plus blood test, showing improved tuberculosis detection and reduced healthcare costs. This strengthens the investment case by enhancing the product's clinical and economic credibility. While this supports Qiagen's long-term potential, the company's immediate focus remains on factors like QIAstat-Dx uptake and macroeconomic pressures affecting margins.",
        "sentiment_score": 0.418728,
        "sentiment_label": "Bullish",
        "relevance_score": 0.966965,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus Evidence - Learn Why",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-qgen/qiagen/news/the-bull-case-for-qiagen-qgen-could-change-following-new-qua/amp",
        "date": "2026-03-30",
        "summary": "QIAGEN N.V. recently released new clinical and health economic data for its QuantiFERON-TB Gold Plus blood test, demonstrating improved tuberculosis detection and reduced lifetime healthcare costs compared to traditional methods. This evidence, supported by extensive studies, strengthens the test's role in preventive treatment and resource efficiency. The report suggests this expanded validation could impact Qiagen's investment narrative, particularly as the company pushes for increased adoption",
        "sentiment_score": 0.409479,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN NV Hits New 52-Week Low at USD 38.80 Amid Declining Performance",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/qiagen-nv-hits-new-52-week-low-at-usd-3880-amid-declining-performance-3926234",
        "date": "2026-03-30",
        "summary": "QIAGEN NV has fallen to a new 52-week low of USD 38.80, marking a 15.36% decline over the past year. Despite strong debt servicing capabilities and record operating cash flow, the company's long-term growth prospects are limited, with operating profit growing at only 5.15% annually over the last five years. The stock's current valuation indicates a complex landscape for investors.",
        "sentiment_score": -0.619085,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection",
        "url": "https://www.sahmcapital.com/news/content/qiagen-qgen-valuation-check-as-new-quantiferon-tb-data-reinforces-leadership-in-tuberculosis-detection-2026-03-28",
        "date": "2026-03-29",
        "summary": "Qiagen (QGEN) is under renewed focus following new clinical and health economic data supporting its QuantiFERON-TB Gold Plus test for tuberculosis detection, alongside an upcoming global online event. Despite recent share price momentum fading, the company's valuation narrative suggests it is 29.6% undervalued, with a fair value of $55.46 against a current trading price of $39.07. This outlook is supported by expected revenue growth, improved margins, and the launch of new high-throughput automa",
        "sentiment_score": 0.305569,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-27:newsml_PexprN21a:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-27",
        "summary": "QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM (the Netherlands Authority For the Financial Markets). The notification details a transaction on March 23, 2026, where BlackRock, Inc. adjusted its holdings in Qiagen N.V. The distribution overview shows BlackRock's total capital interest at 10.44% and voting rights at 11.59%, held indirectly through various subsidiaries.",
        "sentiment_score": 0.0136,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-27:newsml_Pex1mz4Va:0-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-27",
        "summary": "This article announces that BlackRock, Inc. has notified the AFM (the Netherlands Authority For the Financial Markets) of a significant change in its holdings and voting rights in QIAGEN N.V. The notification details the distribution of shares and voting rights by various BlackRock entities, categorizing them into real and potential holdings, and specifies the manner of disposal for some shares. Overall, BlackRock's total holding in QIAGEN N.V. is 10.44% and its total voting rights amount to 11.",
        "sentiment_score": 0.047702,
        "sentiment_label": "Neutral",
        "relevance_score": 0.32818,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-steady-position-in-molecular-diagnostics-amid-sector/69007382",
        "date": "2026-03-27",
        "summary": "Qiagen N.V. (QGEN) maintains a stable position in the molecular diagnostics and life sciences sector, providing essential sample and assay technologies for various applications. The company's diversified business model, global footprint, and focus on high-growth areas like next-generation sequencing and human identification make it an attractive consideration for North American investors seeking exposure to the biotech tools space. While facing competition and regulatory risks, Qiagen's consiste",
        "sentiment_score": 0.489181,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.637,
          "confidence": 0.64
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/qiagen-n-v-stock-steady-position-in-molecular-diagnostics-amid-sector/69007382",
        "date": "2026-03-27",
        "summary": "Qiagen N.V. (NYSE: QGEN) maintains a strong presence in molecular diagnostics and life sciences, offering critical technologies for sample preparation and assay development. The company serves diverse markets including diagnostics, applied testing, and research, benefiting from growth in areas like next-generation sequencing and human identification. With consistent financial performance and a balanced global footprint, Qiagen offers North American investors exposure to stable biotech tools thou",
        "sentiment_score": 0.544459,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.637,
          "confidence": 0.64
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen (NYSE:QGEN) Sets New 52-Week Low - Time to Sell?",
        "url": "https://www.marketbeat.com/instant-alerts/qiagen-nyseqgen-sets-new-52-week-low-time-to-sell-2026-03-27/",
        "date": "2026-03-27",
        "summary": "Qiagen (NYSE:QGEN) recently hit a new 52-week low of $38.89, trading below its 50-day and 200-day moving averages, indicating downward pressure. Despite mixed analyst sentiment (five Buys, seven Holds, one Sell) and an average price target of $55.20, the company did beat modest earnings estimates last quarter and has substantial institutional ownership. The article suggests investors consider whether the current low presents a selling opportunity or if the stock has potential for recovery given ",
        "sentiment_score": -0.219504,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: A Core Player in Molecular Diagnostics for Long-Term Investor Focus",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/qiagen-n-v-stock-a-core-player-in-molecular-diagnostics-for-long-term/68995799",
        "date": "2026-03-26",
        "summary": "Qiagen N.V. (ISIN: NL0012169213) is highlighted as a leading molecular diagnostics and life sciences tools company, offering sample-to-insight solutions across genomics, diagnostics, and pharma research. The article details its business model, core operations emphasizing recurring revenue from consumables, and strong market position in areas like next-generation sequencing and point-of-care testing. It also addresses the company's relevance for North American investors, competitive advantages, a",
        "sentiment_score": 0.805766,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: A Core Player in Molecular Diagnostics for Long-Term Investor Focus",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-a-core-player-in-molecular-diagnostics-for-long-term/68995799",
        "date": "2026-03-26",
        "summary": "Qiagen N.V. is presented as a key player in molecular diagnostics and life sciences tools, offering sample-to-insight solutions across genomics, diagnostics, and pharma research. The company's business model relies on a \"razor-and-blade\" approach with recurring consumable revenues and a strong global presence. North American investors are encouraged to consider Qiagen due to its significant U.S. revenue exposure, Nasdaq listing, dividend policy, and alignment with ESG factors.",
        "sentiment_score": 0.014538,
        "sentiment_label": "Neutral",
        "relevance_score": 0.337016,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN NV Hits New 52-Week Low at USD 39.26 Amid Ongoing Decline",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/qiagen-nv-hits-new-52-week-low-at-usd-3926-amid-ongoing-decline-3916716",
        "date": "2026-03-26",
        "summary": "QIAGEN NV has reached a new 52-week low of USD 39.26, marking a 13.83% decrease in its stock over the past year. Despite strong financial health indicators like a low debt-to-equity ratio and high operating cash flow, the company has struggled with long-term growth and its stock performance has lagged behind the S&P 500. Its current valuation, however, appears discounted compared to peers.",
        "sentiment_score": -0.425955,
        "sentiment_label": "Bearish",
        "relevance_score": 0.955816,
        "sentiment": {
          "label": "negative",
          "score": -0.473,
          "confidence": 0.47
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock faces pressure amid biotech sector volatility and recent market caution",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-faces-pressure-amid-biotech-sector-volatility-and-recent/68988787",
        "date": "2026-03-26",
        "summary": "Qiagen N.V. stock has fallen 0.54% to EUR 35.33 on the Frankfurt exchange, reflecting broader volatility in the biotech sector. This dip, despite Qiagen's strong position in molecular diagnostics and genomics tools, indicates investor caution due to shifting demand dynamics and macroeconomic headwinds. US investors are advised to monitor this potential entry point, as the company's consumables-driven revenue model offers a degree of stability in an otherwise volatile market.",
        "sentiment_score": -0.201226,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Should You Add QIAGEN Stock to Your Portfolio for Now?",
        "url": "http://www.msn.com/en-us/money/topstocks/should-you-add-qiagen-stock-to-your-portfolio-for-now/ar-AA1GFG7j?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-26",
        "summary": "The article discusses whether QIAGEN (QGEN) stock is a good addition to an investment portfolio. Unfortunately, the provided content is incomplete and lacks the detailed analysis necessary to make an informed decision.",
        "sentiment_score": 0.242743,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock faces pressure amid biotech sector volatility and recent price dip on Frankfurt exchange",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-faces-pressure-amid-biotech-sector-volatility-and-recent/68987424",
        "date": "2026-03-25",
        "summary": "Qiagen N.V. (NL0012169213) stock recently dipped by 0.54% to EUR 35.33 on the Frankfurt exchange, reflecting broader pressures within the biotech sector. Despite this short-term selling pressure and market volatility, the company maintains a 'Starkes Signal' rating from analysts, suggesting underlying strength and potential for long-term upside. Key business drivers for Qiagen include its strong position in molecular diagnostics, offering recurring revenue from consumables for genomics and infec",
        "sentiment_score": 0.224294,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Should You Add QIAGEN Stock to Your Portfolio for Now?",
        "url": "https://www.msn.com/en-us/money/topstocks/should-you-add-qiagen-stock-to-your-portfolio-for-now/ar-AA1GFG7j?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-25",
        "summary": "NULL",
        "sentiment_score": 0.106123,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "JPMorgan Chase & Co. Has $33.09 Million Stake in Qiagen N.V. $QGEN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-jpmorgan-chase-co-has-3309-million-stake-in-qiagen-nv-qgen-2026-03-23/",
        "date": "2026-03-23",
        "summary": "JPMorgan Chase & Co. significantly reduced its stake in Qiagen N.V. by 40.9% in the third quarter, now holding 740,649 shares valued at $33.09 million. Despite JPMorgan's reduction, other institutional investors like Vanguard and Amundi increased their positions, and several new stakes were initiated, leading to approximately 70% institutional ownership of Qiagen. Qiagen recently beat earnings estimates and has a consensus \"Hold\" rating with a target price of $55.20 from analysts.",
        "sentiment_score": 0.117707,
        "sentiment_label": "Neutral",
        "relevance_score": 0.9938,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock faces pressure amid genomics slowdown as DACH investors eye biotech resilience",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-faces-pressure-amid-genomics-slowdown-as-dach-investors/68962276",
        "date": "2026-03-22",
        "summary": "Qiagen N.V. shares dipped after mixed Q4 2025 results revealed a 2% revenue decline and slower genomics demand. Despite maintaining its 2026 growth guidance, investors reacted to near-term softness in the genomics segment, though the diagnostics business showed resilience. DACH investors are closely monitoring the stock, given its significance in the European life sciences sector and the potential for recovery through renewed R&D funding and strategic expansions.",
        "sentiment_score": 0.033864,
        "sentiment_label": "Neutral",
        "relevance_score": 0.349673,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Agilent, Danaher could be potential buyers of Qiagen - analyst",
        "url": "https://www.msn.com/en-us/money/companies/agilent-danaher-could-be-potential-buyers-of-qiagen-analyst/ar-AA1UBgHd?ocid=BingNewsVerp",
        "date": "2026-03-22",
        "summary": "This article mentions that an analyst views Agilent and Danaher as potential acquirers for Qiagen. No further details are provided in the current content.",
        "sentiment_score": 0.29806,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen Announces Form 20-F Annual Report Filing for 2025 Results",
        "url": "https://www.businesswire.com/news/home/20260320968222/en/Qiagen-Announces-Form-20-F-Annual-Report-Filing-for-2025-Results",
        "date": "2026-03-21",
        "summary": "QIAGEN N.V. announced it has filed its annual report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. Shareholders can access the document on the company's website or request printed copies free of charge. QIAGEN is a global leader in Sample to Insight solutions for Life Sciences and molecular diagnostics.",
        "sentiment_score": 0.017163,
        "sentiment_label": "Neutral",
        "relevance_score": 0.344521,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock rises on strong Q4 earnings and genomics demand surge amid AI biotech push",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-rises-on-strong-q4-earnings-and-genomics-demand-surge/68944548",
        "date": "2026-03-20",
        "summary": "Qiagen N.V. reported stronger-than-expected Q4 results, with revenue beating estimates by 5% and adjusted EPS surpassing forecasts. The growth was driven by demand for genomic tools, particularly in AI-driven drug discovery and diagnostics, leading to a 4.2% intraday rise in its stock on the Frankfurt Stock Exchange. The company provided a positive 2026 guidance, expecting 7-9% revenue growth and increasing its dividend, highlighting its strong position in genomic innovation and relevance for DA",
        "sentiment_score": 0.455745,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen Announces Form 20-F Annual Report Filing for 2025 Results",
        "url": "https://www.biospace.com/press-releases/qiagen-announces-form-20-f-annual-report-filing-for-2025-results",
        "date": "2026-03-20",
        "summary": "QIAGEN N.V. has filed its annual report on Form 20-F, including audited consolidated financial statements, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is accessible on QIAGEN's website, and shareholders can request printed copies free of charge. QIAGEN is a global leader in Sample to Insight solutions for life sciences and molecular diagnostics, employing approximately 5,700 people worldwide as of December 31, 2025.",
        "sentiment_score": 0.10809,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen Announces Form 20-F Annual Report Filing for 2025 Results",
        "url": "https://sg.finance.yahoo.com/news/qiagen-announces-form-20-f-113000194.html",
        "date": "2026-03-20",
        "summary": "QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced the filing of its annual report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. Shareholders can access the document on QIAGEN's website and request printed copies free of charge. QIAGEN is a Netherlands-based global leader in Sample to Insight solutions for Life Sciences and molecular diagnostics.",
        "sentiment_score": 0.145848,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act]",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-20:newsml_PexCr4Fna:0-pta-cms-qiagen-n-v-third-country-release-according-to-article-50-para-1-no-2-of-the-wphg-the-german-securities-trading-act/",
        "date": "2026-03-20",
        "summary": "QIAGEN N.V. has filed its Form 20-F Annual Report for the fiscal year ended December 31, 2025, with the United States Securities and Exchange Commission (SEC). This announcement serves as a third-country release under Article 50 Para. 1, No. 2 of the German Securities Trading Act, ensuring Europe-wide distribution. The report is now accessible on QIAGEN's corporate website.",
        "sentiment_score": 0.001516,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider",
        "description": "Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies. Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies.",
        "url": "https://www.globenewswire.com/news-release/2026/04/13/3272705/0/en/Companion-Diagnostics-Market-Size-is-Projected-to-Hit-USD-26-38-Billion-by-2035-SNS-Insider.html",
        "date": "2026-04-13",
        "published_at": "2026-04-13T15:30:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.869,
          "confidence": 0.87
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Rapid Growth in Cell-Free Tumor DNA Detection Market: Forecast to Reach $5.64 Billion by 2030 as Advancements in Personalized Medicine Propel Expansion",
        "description": "Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The \"Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Report 2026\" has been added to ResearchAndMarkets.com's offering.",
        "url": "https://www.globenewswire.com/news-release/2026/04/07/3269503/28124/en/Rapid-Growth-in-Cell-Free-Tumor-DNA-Detection-Market-Forecast-to-Reach-5-64-Billion-by-2030-as-Advancements-in-Personalized-Medicine-Propel-Expansion.html",
        "date": "2026-04-07",
        "published_at": "2026-04-07T16:23:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Molecular Tumor Board Solutions Market Outlook 2026-2030 & 2035 with Competitor Market Share Data",
        "description": "Key growth factors include expanding precision oncology programs, genomic data integration, and cloud deployment in healthcare, with strong potential in Asia-Pacific Key growth factors include expanding precision oncology programs, genomic data integration, a…",
        "url": "https://www.globenewswire.com/news-release/2026/04/07/3269500/28124/en/Molecular-Tumor-Board-Solutions-Market-Outlook-2026-2030-2035-with-Competitor-Market-Share-Data.html",
        "date": "2026-04-07",
        "published_at": "2026-04-07T16:15:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.832,
          "confidence": 0.83
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider",
        "description": "Molecular diagnostics market to grow from $18.26 Bn to $43.50 Bn by 2035, driven by PCR, NGS, and demand for early, precise diagnosis....",
        "url": "https://www.globenewswire.com/news-release/2026/04/03/3267957/0/en/Molecular-Diagnostics-Market-Size-is-Expected-to-Reach-USD-43-50-Billion-by-2035-Owing-to-the-Surging-Demand-for-Accurate-and-Early-Disease-Detection-Globally-SNS-Insider.html",
        "date": "2026-04-03",
        "published_at": "2026-04-03T09:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Gene Panel Market Size to Projected Reach USD 17.18 Billion by 2035, Driven by Precision Medicine Adoption – SNS Insider",
        "description": "Rising demand for early disease detection, expanding oncology applications, and rapid advancements in next-generation sequencing technologies propel market growth at 16.69% CAGR. Rising demand for early disease detection, expanding oncology applications, and …",
        "url": "https://www.globenewswire.com/news-release/2026/03/30/3264508/0/en/Gene-Panel-Market-Size-to-Projected-Reach-USD-17-18-Billion-by-2035-Driven-by-Precision-Medicine-Adoption-SNS-Insider.html",
        "date": "2026-03-30",
        "published_at": "2026-03-30T11:12:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.178,
          "confidence": 0.18
        }
      },
      {
        "source": "news",
        "source_name": "PR Newswire UK",
        "title": "Human Identification Market worth $1.69 billion by 2031 | MarketsandMarkets™",
        "description": "DELRAY BEACH, Fla., March 27, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Human Identification Market is projected to grow from about USD 1.01 billion in 2026 to USD 1.69 billion by 2031, at a CAGR of 10.9%. Browse 285 market data tables and 60 …",
        "url": "https://www.prnewswire.co.uk/news-releases/human-identification-market-worth-1-69-billion-by-2031--marketsandmarkets-302727035.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T14:01:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "news",
        "source_name": "Nature.com",
        "title": "Genomic history of early dogs in Europe",
        "description": "Genome-wide analysis shows European dogs existed by 14,200 years ago, were already genetically distinct, received less Neolithic Southwest Asian admixture than humans did and contributed substantially to later European dogs.",
        "url": "https://www.nature.com/articles/s41586-026-10112-7",
        "date": "2026-03-25",
        "published_at": "2026-03-25T00:00:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Predictive Biomarkers Market to Reach USD 156.85 Billion by 2035; Rising Adoption of Precision Medicine and Targeted Therapies Driving Market Growth – SNS Insider",
        "description": "Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel Unprecedented Market Expansion. Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel U…",
        "url": "https://www.globenewswire.com/news-release/2026/03/17/3257053/0/en/Predictive-Biomarkers-Market-to-Reach-USD-156-85-Billion-by-2035-Rising-Adoption-of-Precision-Medicine-and-Targeted-Therapies-Driving-Market-Growth-SNS-Insider.html",
        "date": "2026-03-17",
        "published_at": "2026-03-17T11:45:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.477,
          "confidence": 0.48
        }
      }
    ]
  }
}